Print Page  Close Window

News Release

Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference

EMERYVILLE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22, 2017, in New York, NY.

   
Zogenix Presentation Details
Date: Wednesday, March 22, 2017
Time: 2:10 pm Eastern Time / 11:10 am Pacific Time
Location: New York, NY - Westin New York Grand Central Hotel
   

The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.                                  

About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

CONTACT:     Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Primary Logo

Zogenix, Inc.